The Effects of Lu-177 PSMA-PRLT from April 2013 to April 2016.

Over the course of three years at Bad Berka, 119 metastatic castration-resistant prostate cancer patients were treated with 300 total cycles of PRLT. Patients received from 1 to 7 cycles. Bone mets were present in 81% of patients, 71% presented with lymph node mets and 16% presented with visceral mets.

Patients who had at least one cycle of PRLT (80 patients) experienced a reduction of the PSA level. Some 61 patients had a reduction of more than 30% in their PSA. Another 22 patients had a reduction of over 80% in their PSA. Two patients showed complete remission – no detectable PSA after the treatment. 

Tolerance of PRLT

Overall, patients tolerated the treatment well as no severe acute or long-term side-effects were seen over a period of 34 months of monitoring. The most common adverse effect was mild fatigue lasting a few days after therapy. A few patients (5) reported mild dryness of the mouth. Notable were two observations: 1) there was an absence of diarrhea despite significant intestinal uptake and 2) there was no evidence of renal toxicity after PRLT, except for a small number of patients who had been heavily pretreated with chemotherapy and had already experienced bone marrow compromise.